STZ depletes pancreatic β cells, thereby lowering systemic insulin levels (Fig. 8A and B) and severely disrupting glucose homeostasis as indicated by sustained hyperglycemia after an intraperitoneally injected glucose load (Fig. 8C). This evidence concerns the gene INS and Hyperglycemia.